Skip to main content
Search
Search
Quick Search anywhere
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Skip main navigation
JACC Journals › JACC: CardioOnc › Archives › Vol. 2 No. 2
Previous
Next

Computed Tomographic Angiography Assessment of Epicardial Coronary Vasoreactivity for Early Detection of Doxorubicin-Induced CardiotoxicityOpen Access

Original Research

J Am Coll Cardiol CardioOnc. 2020 Jun, 2 (2) 207–219
Topic(s):
Editorial Comment: Anthracycline Cardiotoxicity: Can CT Move Us Further?∗
Sections

Central Illustration

Abstract

Background

The vascular endothelium is a novel target for the detection, management, and prevention of doxorubicin (DOX)-induced cardiotoxicity.

Objectives

The study aimed to: 1) develop a methodology by computed tomography angiography (CTA) to evaluate stress-induced changes in epicardial coronary diameter; and 2) apply this to a chronic canine model of DOX-induced cardiotoxicity to assess vascular toxicity.

Methods

To develop and validate quantitative methods, sequential retrospectively gated coronary CTAs were performed in 16 canines. Coronary diameters were measured at prespecified distances during rest, adenosine (ADE) (280 μg/kg/min), rest 30 min post-ADE, and dobutamine (DOB) (5 μg/kg/min). A subgroup of 8 canines received weekly intravenous DOX (1 mg/kg) for 12 to 15 weeks, followed by rest-stress CTA at cumulative doses of ∼4-mg/kg (3 to 5 mg/kg), ∼8-mg/kg (7 to 9 mg/kg), and ∼12-mg/kg (12 to 15 mg/kg) of DOX. Echocardiograms were performed at these timepoints to assess left ventricular ejection fraction and global longitudinal strain.

Results

Under normal conditions, epicardial coronary arteries reproducibly dilated in response to ADE (left anterior descending coronary artery [LAD]: 12 ± 2%, left circumflex coronary artery [LCx]: 13 ± 2%, right coronary artery [RCA]: 14 ± 2%) and DOB (LAD: 17 ± 3%, LCx: 18 ± 2%, RCA: 15 ± 3%). With DOX, ADE vasodilator responses were impaired after ∼4-mg/kg (LAD: –3 ± 1%, LCx: 0 ± 2%, RCA: –5 ± 2%) and ∼8-mg/kg (LAD: –3 ± 1%, LCx: 0 ± 1%, RCA: –2 ± 2%). The DOB dilation response was preserved at ∼4-mg/kg of DOX (LAD: 18 ± 4%, LCx: 11 ± 3%, RCA: 11 ± 2%) but tended to decrease at ∼8-mg/kg of DOX (LAD: 4 ± 2%, LCx: 8 ± 3%, RCA: 3 ± 2%). A significant left ventricular ejection fraction reduction was observed only at 12 to 15 mg/kg DOX (baseline: 63 ± 2%, 12-mg/kg: 45 ± 3%). Global longitudinal strain was abnormal at ∼4-mg/kg of DOX (p = 0.011).

Conclusions

CTA can reliably assess epicardial coronary diameter in response to pharmacological stressors, providing a noninvasive functional index of coronary vasoreactivity. Impaired epicardial vasodilation occurs early in DOX-induced cardiotoxicity.

References

  • 1. Hashim D., Boffetta P., La Vecchia C., et al. "The global decrease in cancer mortality: trends and disparities". Ann Oncol 2016;27:926-933.

    CrossrefMedlineGoogle Scholar

  • 2. Oikonomou E.K., Athanasopoulou S.G., Kampaktsis P.N., et al. "Development and validation of a clinical score for cardiovascular risk stratification of long-term childhood cancer survivors". Oncologist 2018;23:965-973.

    CrossrefMedlineGoogle Scholar

  • 3. Yeh E.T., Bickford C.L. "Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management". J Am Coll Cardiol 2009;53:2231-2247.

    View ArticleGoogle Scholar

  • 4. Von Hoff D.D., Layard M.W., Basa P., et al. "Risk factors for doxorubicin-induced congestive heart failure". Ann Intern Med 1979;91:710-717.

    CrossrefMedlineGoogle Scholar

  • 5. Cardinale D., Colombo A., Bacchiani G., et al. "Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy". Circulation 2015;131:1981-1988.

    CrossrefMedlineGoogle Scholar

  • 6. Cardinale D., Colombo A., Lamantia G., et al. "Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy". J Am Coll Cardiol 2010;55:213-220.

    View ArticleGoogle Scholar

  • 7. Hamo C.E., Bloom M.W., Cardinale D., et al. "Cancer therapy-related cardiac dysfunction and heart failure: part 2: prevention, treatment, guidelines, and future directions". Circ Heart Fail 2016;9:e002843.

    CrossrefGoogle Scholar

  • 8. Ewer M.S., Ali M.K., Mackay B., et al. "A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin". J Clin Oncol 1984;2:112-117.

    CrossrefMedlineGoogle Scholar

  • 9. Yancy C.W., Jessup M., Bozkurt B., et al. "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol 2013;62:e147-e239.

    View ArticleGoogle Scholar

  • 10. Andreini D., Pontone G., Pepi M., et al. "Diagnostic accuracy of multidetector computed tomography coronary angiography in patients with dilated cardiomyopathy". J Am Coll Cardiol 2007;49:2044-2050.

    View ArticleGoogle Scholar

  • 11. Bhatti S., Hakeem A., Yousuf M.A., Al-Khalidi H.R., Mazur W., Shizukuda Y. "Diagnostic performance of computed tomography angiography for differentiating ischemic vs nonischemic cardiomyopathy". J Nucl Cardiol 2011;18:407-420.

    CrossrefMedlineGoogle Scholar

  • 12. Daher I.N., Banchs J., Yusuf S.W., Mouhayar E., Durand J.B., Gladish G. "Impact of cardiac computed tomographic angiography findings on planning of cancer therapy in patients with concomitant structural heart disease". Cardiol Res Pract 2011;2011:268058.

    CrossrefMedlineGoogle Scholar

  • 13. Kotamraju S., Konorev E.A., Joseph J., Kalyanaraman B. "Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species". J Biol Chem 2000;275:33585-33592.

    CrossrefMedlineGoogle Scholar

  • 14. Monti M., Terzuoli E., Ziche M., Morbidelli L. "The sulphydryl containing ACE inhibitor Zofenoprilat protects coronary endothelium from doxorubicin-induced apoptosis". Pharmacol Res 2013;76:171-181.

    CrossrefMedlineGoogle Scholar

  • 15. Majzner K., Wojcik T., Szafraniec E., et al. "Nuclear accumulation of anthracyclines in the endothelium studied by bimodal imaging: fluorescence and Raman microscopy". Analyst 2015;140:2302-2310.

    CrossrefMedlineGoogle Scholar

  • 16. Vasquez-Vivar J., Martasek P., Hogg N., Masters B.S., Pritchard K.A., Kalyanaraman B. "Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin". Biochemistry 1997;36:11293-11297.

    CrossrefMedlineGoogle Scholar

  • 17. Feng Q., Song W., Lu X., et al. "Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase". Circulation 2002;106:873-879.

    CrossrefMedlineGoogle Scholar

  • 18. Sacco G., Mario B., Lopez G., Evangelista S., Manzini S., Maggi C.A. "ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat". Vascul Pharmacol 2009;50:166-170.

    CrossrefMedlineGoogle Scholar

  • 19. Rasanen M., Degerman J., Nissinen T.A., et al. "VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection". Proc Natl Acad Sci U S A 2016;113:13144-13149.

    CrossrefMedlineGoogle Scholar

  • 20. Luu A.Z., Chowdhury B., Al-Omran M., Teoh H., Hess D.A., Verma S. "Role of endothelium in doxorubicin-induced cardiomyopathy". J Am Coll Cardiol Basic Trans Science 2018;3:861-870.

    View ArticleGoogle Scholar

  • 21. Herman E.H., Ferrans V.J. "Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187)". Cancer Res 1981;41:3436-3440.

    MedlineGoogle Scholar

  • 22. Stendahl J.C., Parajuli N., Lu A., et al. "Regional myocardial strain analysis via 2D speckle tracking echocardiography: validation with sonomicrometry and correlation with regional blood flow in the presence of graded coronary stenoses and dobutamine stress". Cardiovasc Ultrasound 2020;18:2.

    CrossrefMedlineGoogle Scholar

  • 23. Montgomery R.R., Booth C.J., Wang X., Blaho V.A., Malawista S.E., Brown C.R. "Recruitment of macrophages and polymorphonuclear leukocytes in Lyme carditis". Infect Immun 2007;75:613-620.

    CrossrefMedlineGoogle Scholar

  • 24. Boutagy N.E., Wu J., Cai Z., et al. "In vivo reactive oxygen species detection with a novel positron emission tomography tracer, (18)F-DHMT, allows for early detection of anthracycline-induced cardiotoxicity in rodents". J Am Coll Cardiol Basic Trans Science 2018;3:378-390.

    View ArticleGoogle Scholar

  • 25. Lupi A., Buffon A., Finocchiaro M.L., Conti E., Maseri A., Crea F. "Mechanisms of adenosine-induced epicardial coronary artery dilatation". Eur Heart J 1997;18:614-617.

    CrossrefMedlineGoogle Scholar

  • 26. Hodgson J.M., Cohen M.D., Szentpetery S., Thames M.D. "Effects of regional alpha- and beta-blockade on resting and hyperemic coronary blood flow in conscious, unstressed humans". Circulation 1989;79:797-809.

    CrossrefMedlineGoogle Scholar

  • 27. Ruffolo R.R. "The pharmacology of dobutamine". Am J Med Sci 1987;294:244-248.

    CrossrefMedlineGoogle Scholar

  • 28. Barbato E., Bartunek J., Wyffels E., Wijns W., Heyndrickx G.R., De Bruyne B. "Effects of intravenous dobutamine on coronary vasomotion in humans". J Am Coll Cardiol 2003;42:1596-1601.

    View ArticleGoogle Scholar

  • 29. Rossi A., Papadopoulou S.L., Pugliese F., et al. "Quantitative computed tomographic coronary angiography: does it predict functionally significant coronary stenoses?"Circ Cardiovasc Imaging 2014;7:43-51.

    CrossrefMedlineGoogle Scholar

  • 30. Min J.K., Leipsic J., Pencina M.J., et al. "Diagnostic accuracy of fractional flow reserve from anatomic CT angiography". JAMA 2012;308:1237-1245.

    CrossrefMedlineGoogle Scholar

  • 31. Farsalinos K.E., Daraban A.M., Unlu S., Thomas J.D., Badano L.P., Voigt J.U. "Head-to-head comparison of global longitudinal strain measurements among nine different vendors: the EACVI/ASE inter-vendor comparison study". J Am Soc Echocardiogr 2015;28:1171-1181, e2.

    CrossrefMedlineGoogle Scholar

  • 32. Toro-Salazar O.H., Lee J.H., Zellars K.N., et al. "Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines". Cardiooncology 2018;4:4.

    MedlineGoogle Scholar

  • 33. Park S.M., Hong S.J., Kim Y.H., Ahn C.M., Lim D.S., Shim W.J. "Predicting myocardial functional recovery after acute myocardial infarction: relationship between myocardial strain and coronary flow reserve". Korean Circ J 2010;40:639-644.

    CrossrefMedlineGoogle Scholar

  • 34. Ojaghi-Haghighi Z., Abtahi F., Fazlolah S., Moladoust H., Maleki M., Gholami S. "Coronary flow reserve, strain and strain rate imaging during pharmacological stress before and after percutaneous coronary intervention: comparison and correlation". Echocardiography 2011;28:570-574.

    CrossrefMedlineGoogle Scholar

  • 35. Russell R.R., Alexander J., Jain D., et al. "The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy". J Nucl Cardiol 2016;23:856-884.

    CrossrefMedlineGoogle Scholar

  • 36. Jordan J.H., D'Agostino R.B., Hamilton C.A., et al. "Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance". Circ Cardiovasc Imaging 2014;7:872-879.

    CrossrefMedlineGoogle Scholar

  • 37. Neilan T.G., Coelho-Filho O.R., Pena-Herrera D., et al. "Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines". Am J Cardiol 2012;110:1679-1686.

    CrossrefMedlineGoogle Scholar

  • 38. Drafts B.C., Twomley K.M., D'Agostino R.et al. "Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease". J Am Coll Cardiol Img 2013;6:877-885.

    View ArticleGoogle Scholar

  • 39. Bennink R.J., van den Hoff M.J., van Hemert F.J., et al. "Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats". J Nucl Med 2004;45:842-848.

    MedlineGoogle Scholar

  • 40. Saito K., Takeda K., Okamoto S., et al. "Detection of doxorubicin cardiotoxicity by using iodine-123 BMIPP early dynamic SPECT: quantitative evaluation of early abnormality of fatty acid metabolism with the Rutland method". J Nucl Cardiol 2000;7:553-561.

    CrossrefMedlineGoogle Scholar

  • 41. Carrio I., Estorch M., Berna L., Lopez-Pousa J., Tabernero J., Torres G. "Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity". J Nucl Med 1995;36:2044-2049.

    MedlineGoogle Scholar

  • 42. Gharanei M., Hussain A., Janneh O., Maddock H. "Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor". PLoS One 2013;8:e77713.

    CrossrefMedlineGoogle Scholar

  • 43. Laursen A.H., Elming M.B., Ripa R.S., et al. "Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients". J Nucl Cardiol 2018Oct8. [E-pub ahead of print].

    CrossrefGoogle Scholar

  • 44. Cole M.P., Chaiswing L., Oberley T.D., et al. "The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity". Cardiovasc Res 2006;69:186-197.

    CrossrefMedlineGoogle Scholar

  • 45. Finkelman B.S., Putt M., Wang T., et al. "Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer". J Am Coll Cardiol 2017;70:152-162.

    View ArticleGoogle Scholar

  • 46. Octavia Y., Kararigas G., de Boer M., et al. "Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase". J Cell Mol Med 2017;21:3277-3287.

    CrossrefMedlineGoogle Scholar

  • 47. Duquaine D., Hirsch G.A., Chakrabarti A., et al. "Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase". Vasc Med 2003;8:101-107.

    CrossrefMedlineGoogle Scholar

  • 48. Chow A.Y., Chin C., Dahl G., Rosenthal D.N. "Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study". J Clin Oncol 2006;24:925-928.

    CrossrefMedlineGoogle Scholar

  • 49. Brouwer C.A., Postma A., Hooimeijer H.L., et al. "Endothelial damage in long-term survivors of childhood cancer". J Clin Oncol 2013;31:3906-3913.

    CrossrefMedlineGoogle Scholar

  • 50. Robison T.W., Giri S.N. "Effects of chronic administration of doxorubicin on myocardial beta-adrenergic receptors". Life Sci 1986;39:731-736.

    CrossrefMedlineGoogle Scholar

  • 51. Rochitte C.E., George R.T., Chen M.Y., et al. "Computed tomography angiography and perfusion to assess coronary artery stenosis causing perfusion defects by single photon emission computed tomography: the CORE320 study". Eur Heart J 2014;35:1120-1130.

    CrossrefMedlineGoogle Scholar

  • 52. Takx R.A., Sucha D., Park J., Leiner T., Hoffmann U. "Sublingual nitroglycerin administration in coronary computed tomography angiography: a systematic review". Eur Radiol 2015;25:3536-3542.

    CrossrefMedlineGoogle Scholar